China’s pharma contractors rally as US supply chain pressures face industry resistance

Chinese pharmaceutical contractors are demonstrating financial resilience despite US efforts to reduce reliance on their supply chains. Investors are optimistic as US measures aimed at curbing China's global pharmaceutical supplier status have encountered resistance from industry players unwilling to abandon China's cost advantages. This resistance is reflected in the stock performance of major Chinese pharmaceutical contractors, with Hong Kong-listed shares of WuXi AppTec and Genscript Biotech seeing significant gains. WuXi AppTec, a leading contract pharmaceutical research provider, and Genscript Biotech, the world's largest gene synthesis service provider, both experienced notable increases in their stock prices on Monday.